İnflamatuar Bağırsak Hastalıkları Olan Bireylerde İlaç Uyumu ve Yaşam Kalitesi

Yıl 2020, Cilt: 2 Sayı: 3, 192 - 199, 22.12.2020

Nazli Öztürk Yasemin Yıldırım

https://doi.org/10.46413/boneyusbad.770410

Öz

İİnflamatuar bağırsak hastalıkları genetik, çevresel, immün sistem gibi birçok faktörün sorumlu tutulduğu nedeni tam olarak bilinmeyen gastrointestinal sistemin kronik inflamasyonudur. Dünya genelinde inflamatuar bağırsak hastalıklarının insidans ve prevelansının gün geçtikçe artması, kronik olması, ömür boyu ilaç kullanımını gerektirmesi, rölapsların önlenmesi ve remisyonun sağlanabilmesi için ilaç uyumunun üst düzeyde olması önemlidir. Bu derlemenin amacı inflamatuar bağırsak hastalıkları olan bireylerde ilaç uyumu ve yaşam kalitesi arasındaki ilişkiyi incelemektir. Sağlık profesyoneli olan hemşireler ekip işbirliği ile hastaların ilaç uyumunun arttırılmasına yardımcı olarak yaşam kalitesinin yükseltilmesine katkıda bulunabilir.

Anahtar Kelimeler

İnflamatuar bağırsak hastalıkları, İlaç uyumu, Yaşam kalitesi

Drug Compliance and Quality of Life in Patients With Inflammatory Bowel Disease

Öz

Inflammatory bowel diseases is a chronic inflammation of the gastrointestinal tract, which is not known exactly why many factors such as genetics, environmental and immune system are held responsible. It is important to have a high level of drug compliance in order to increase the incidence and prevalence of inflammatory bowel diseases worldwide day by day, to be chronic and to require life-long drug use, to prevent relapses and to ensure remission. The aim of this review is to examine the relationship between drug compliance and quality of life in individuals with inflammatory bowel diseases. Nurses, who are health professionals, can help improve the quality of life of the patients by helping to increase drug compliance of the patients with team collaboration.

Anahtar Kelimeler

Inflammatory bowel diseases, Drug compliance, Quality of life

Kaynakça

• Campos, S., Portela, F., Sousa, P., & Sofia, C. (2016). Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. European Journal of Gastroenterology & hepatology, 28(11), 1313-1319. doi:10.1097/MEG.0000000000000704.
• Davis, S. C., Robinson, B. L., Vess, J., & Lebel, J. S. (2018). Primary care management of ulcerative colitis. The Nurse Practitioner, 43(1), 11-19.
• Dewulf, N. D. L. S., Monteiro, R. A., Passos, A. D. C., Vieira, E. M., & Troncon, L. E. D. A. (2007). Compliance to drug therapy in inflammatory bowel diseases outpatients from an university hospital. Arquivos de gastroenterologia, 44(4), 289-296. doi:10.1590/s0004-28032007000400003.
• Fiorino, G., Allocca, M., Chaparro, M., Coenen, S., Fidalgo, C., Younge, L., et al. (2019). ‘Quality of care’standards in inflammatory bowel disease: a systematic review. Journal of Crohn's and Colitis, 13(1), 127-137. doi: 10.1093/ecco-jcc/jjy140.
• Ghadir, M. R., Bagheri, M., Vahedi, H., Daryani, N. E., Malekzadeh, R., Hormati, A., et al. (2016). Nonadherence to medication in inflammatory bowel disease: rate and reasons. Middle East Journal of Digestive Diseases, 8(2), 116. doi: 10.15171/mejdd.2016.16.
• Gracie, D. J., Irvine, A. J., Sood, R., Mikocka-Walus, A., Hamlin, P. J., & Ford, A. C. (2017). Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 2(3), 189-199. doi:10.1016/S2468-1253(16)30206-0.
• Habibi, F., Habibi, M. E., Gharavinia, A., Mahdavi, S. B., Akbarpour, M. J., Baghaei, A., et al. (2017). Quality of life in inflammatory bowel disease patients: A cross-sectional study. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, 22. doi: 10.4103/jrms.JRMS_975_16.
• Hromadkova, L., Soukup, T., Cermakova, E., & Vlcek, J. (2012). Drug compliance in patients with systemic scleroderma. Clinical Rheumatology, 31(11), 1577-1583. doi: 10.1007/s10067-012-2050-0.
• Horváth, G., Farkas, K., Hollósi, R., Nagy, F., Szepes, Z., Papp, M., et al. (2012). Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?. Scandinavian Journal of Gastroenterology, 47(11), 1298-1303. doi: 10.3109/00365521.2012.703233.
• Hwang, J. H., & Yu, C. S. (2019). Depression and resilience in ulcerative colitis and Crohn's disease patients with ostomy. International Wound Journal, 16, 62-70. doi: 10.1111/iwj.13076.
• Khanna, R., Nelson, S. A., Feagan, B. G., D'Haens, G., Sandborn, W. J., Zou, G. Y., et al. (2016). Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database of Systematic Reviews, (8). doi: 10.1002/14651858.CD010642.
• Kózka, M., Skowron, W., & Bodys-Cupak, I. (2019). Determinants of the level of anxiety and fears in a group of patients with ulcerative colitis. Annals of Agricultural And Environmental Medicine: AAEM, 26(2), 337-340. doi: 10.26444/aaem/94651.
• Lee, S. H., eun Kwon, J., & Cho, M. L. (2018). Immunological pathogenesis of inflammatory bowel disease. Intestinal Research, 16(1), 26. doi: 10.5217/ir.2018.16.1.26.
• Lönnfors, S., Vermeire, S., & Avedano, L. (2014). IBD and health-related quality of life—discovering the true impact. Journal of Crohn's and Colitis, 8(10), 1281-1286. doi: 10.1016/j.crohns.2014.03.005.
• Mahalli, A. A., & Alharthi, H. M. (2017). Assessment of health-related quality of life of patients with inflammatory bowel diseases in Eastern Province, Saudi Arabia. Journal of Infection and Public Health, 10(1), 93-101. doi: 10.1016/j.jiph.2016.02.008.
• Malinowski, B., Wiciński, M., Sokołowska, M. M., Hill, N. A., & Szambelan, M. (2020). The Rundown of Dietary Supplements and Their Effects on Inflammatory Bowel Disease—A Review. Nutrients, 12(5), 1423. doi: 10.3390/nu12051423.
• Manmohan, T., Sreenivas, G., Sastry, V. V., Sudha Rani, E., Indira, K., & Ushasree, T. (2012). Drug compliance and adherence to treatment. Journal of Medical and Dental Sciences, 1, 142-159.
• Martelli, L., Lopez, A., Strobel, S., Danese, S., Roblin, X., & Baumann, C. (2017). Adherence to infliximab therapy in inflammatory bowel disease patients in a real‐life setting. Journal of Digestive Diseases, 18(10), 566-573. doi: 10.1111/1751-2980.12539.
• Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487-497. doi: 10.1056/NEJMra050100.
• Park, K. T., Ehrlich, O. G., Allen, J. I., Meadows, P., Szigethy, E. M., Henrichsen, K., et al. (2020). The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflammatory Bowel Diseases, 26(1), 1-10. doi: 10.1093/ibd/izz104.
• Perry, J., Chen, A., Kariyawasam, V., Collins, G., Choong, C., Teh, W. L. et al. (2018). Medication non-adherence in inflammatory bowel diseases is associated with disability. Intestinal Research, 16(4), 571. doi: 10.5217/ir.2018.00033.
• Pudipeddi, A., Kariyawasam, V., Haifer, C., Baraty, B., Paramsothy, S., & Leong, R. W. (2019). Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety, 18(5), 357-367. doi: 10.1080/14740338.2019.1612874.
• Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG clinical guideline: ulcerative colitis in adults. American Journal of Gastroenterology, 114(3), 384-413. doi: 10.14309/ajg.0000000000000152.
• Öztürk N., Yıldırım Y. (2018). İnflamatuar Bağırsak Hastalıkları Olan Bireylerde İlaç Uyumu ile Yaşam Kalitesi Arasındaki İlişki. Ege Üniversitesi Sağlık Bilimleri Enstitüsü, Yüksek Lisans Tezi.
• Seyedian, S. S., Nokhostin, F., & Malamir, M. D. (2019). A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life, 12(2), 113. doi: 10.25122/jml-2018-0075.
• Stansfield, C. (2016). Considerations in the management of ulcerative colitis. Gastrointestinal Nursing, 14(7), 42-50. doi: 10.12968/gasn.2016.14.7.42.
• Trindade, A. J., Ehrlich, A., Kornbluth, A., & Ullman, T. A. (2010). Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflammatory Bowel Diseases, 17(2), 599-604. doi: 10.1002/ibd.21310.
• Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn's disease. The Lancet, 389(10080), 1741-1755. doi:10.1016/S0140-6736(16)31711-1.
• Vlasnik, J. J., Aliotta, S. L., & DeLor, B. (2005). Medication adherence: factors influencing compliance with prescribed medication plans. The Case Manager, 16(2), 47-51. doi: 10.1016/j.casemgr.2005.01.009.
• Yoon, J. Y., Shin, J. E., Park, S. H., Park, D. I., & Cha, J. M. (2017). Disability due to inflammatory bowel disease is correlated with drug compliance, disease activity, and quality of life. Gut and Liver, 11(3), 370. doi:10.5009/gnl16422.
• Zargar, A., Gooraji, S. A., Keshavarzi, B., & Aghamohammadi, A. A. H. (2019). Effect of irritable bowel syndrome on sleep quality and quality of life of inflammatory bowel disease in clinical remission. International Journal of Preventive Medicine, 10. doi:10.4103/ijpvm.IJPVM_364_17.